MedTrace Logo

PEMF Therapy to Treat Lingering Symptoms of Lyme Disease After Treatment With Antibiotics

NCT04577053 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-04-13

No results posted yet for this study

Summary

Overview

PEMF Therapy for relief or reduction of lingering symptoms after antibiotic treatment of Lyme disease of participants in the UK.

Symptoms monitored:

Muscle ache, myalgia, muscle pain that is acutely located and/or 'wandering' (different location on different days) Aching joints Headache Fatigue, general tiredness, loss of energy, general exhaustion Mild, recurrent fever and/or chills occurring regularly Lack of oxygen in blood, feelings of 'air hunger', too high carbon dioxide levels in blood

Conditions

  • Lyme Disease
  • Lyme Neuroborreliosis
  • Lyme Arthritis
  • Unknown Origin Fever

Interventions

DEVICE

Scientific Consciousness Interface Operations (SCIO) Class II FDA approved medical device

Manufactured by QX World Ltd. in Budapest, Hungary

Sponsors & Collaborators

  • Kasey Phifer

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
14 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-07
Primary Completion
2020-12-04
Completion
2021-09-28

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04577053 on ClinicalTrials.gov